Citigroup Inc X4 Pharmaceuticals, Inc Transaction History
Citigroup Inc
- $163 Billion
- Q4 2024
A detailed history of Citigroup Inc transactions in X4 Pharmaceuticals, Inc stock. As of the latest transaction made, Citigroup Inc holds 137,207 shares of XFOR stock, worth $54,882. This represents 0.0% of its overall portfolio holdings.
Number of Shares
137,207
Previous 125,080
9.7%
Holding current value
$54,882
Previous $83,000
26.51%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding XFOR
# of Institutions
97Shares Held
99.6MCall Options Held
421KPut Options Held
80.6K-
Bain Capital Life Sciences Investors, LLC Boston, MA16.9MShares$6.77 Million3.52% of portfolio
-
Nea Management Company, LLC Timonium, MD15MShares$5.99 Million0.82% of portfolio
-
Black Rock Inc. New York, NY10.7MShares$4.27 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.2MShares$3.28 Million0.0% of portfolio
-
Acorn Capital Advisors, LLC New York, NY7.31MShares$2.92 Million2.9% of portfolio
About X4 Pharmaceuticals, Inc
- Ticker XFOR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 68,646,096
- Market Cap $27.5M
- Description
- X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase...